Multi-Step Synthesis of Chimeric Nutlin-DCA Compounds Targeting Dual Pathways for Treatment of Cancer

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Cancer cells exhibit altered metabolism (Warburg effect) and p53 pathway dysregulation, promoting survival and proliferation.
• Targeting these critical events offers a potential strategy for developing novel anticancer therapies.
• Chimeric compounds, linking multiple pharmacophores, can simultaneously address several cancer-related pathways.

Purpose of the Study:

• To design and synthesize novel multi-functional molecules by linking dichloroacetate (DCA) and Nutlin-3a.
• To evaluate the in vitro anticancer efficacy of these chimeric compounds.
• To investigate the potential of simultaneously targeting the Warburg effect and p53 pathway.

Main Methods:

• Synthesis of novel Nutlin-DCA chimeric compounds using a chemoenzymatic multi-step procedure.
• Inclusion of a key lipase-catalyzed asymmetric reaction during synthesis.
• In vitro biological evaluation of synthesized compounds in a panel of three cancer cell lines.

Main Results:

• Synthesized Nutlin-DCA chimeras demonstrated promising in vitro anticancer activity.
• Specific compounds (rac-19a, rac-19b, rac-20a, rac-20b, and enantioenriched 20a) significantly reduced cancer cell viability at micromolar concentrations.
• The results indicate potent cytotoxic effects against tested cancer cell lines.

Conclusions:

• Simultaneously targeting the Warburg effect and the p53 pathway with a single molecule is a viable therapeutic strategy.
• The developed Nutlin-DCA chimeras represent promising lead compounds for future cancer drug development.
• Further research is warranted to explore the therapeutic potential of these multi-targeting agents.